MDxHealth Announces its Ordinary and Extraordinary General Shareholders’ Meetings
25 Abril 2023 - 5:00PM
MDxHealth Announces its Ordinary and Extraordinary General
Shareholders’ Meetings
NEWS RELEASE – REGULATED
INFORMATIONAPRIL
25, 2023,
4:00 pm ET/
22:00 CET
IRVINE, CA, and
HERSTAL, BELGIUM – April 25, 2023
– MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the
"Company" or
"mdxhealth"), a commercial-stage
precision diagnostics company, today invites the holders of
securities issued by the Company to its ordinary and extraordinary
general shareholders' meetings that will be held on Thursday, May
25, 2023 at 3:00 p.m., Belgian time.
The items on the agenda of the ordinary and
extraordinary general shareholders' meetings include the proposed
approval of a number of resolutions relating to the financial year
ended on 31 December 2022, as well as the renewal of board
mandates, the issuance of a new share option plan called the "2023
Share Option Plan" and the renewal of the authorization to the
board of directors to increase the share capital within the
framework of the authorized capital.
In order to participate to the ordinary and
extraordinary general shareholders’ meetings of the Company, the
holders of securities issued by the Company must comply with
article 7:134, §2, first indent of the Belgian Companies and
Associations Code and the articles of association of the Company,
and fulfill the formalities described in the convening notice. The
convening notice, forms and other documents relating to the
ordinary and extraordinary general shareholders’ meetings can be
consulted on the Company’s website.
The Company recommends holders of its securities
to use e-mail for all communication with the Company regarding the
general shareholders' meetings. The Company's email address for
such communication is: agsm@mdxhealth.com.
About mdxhealth®
mdxhealth is a commercial-stage precision
diagnostics company that provides actionable molecular information
to personalize patient diagnosis and treatment. The Company’s tests
are based on proprietary genomic, epigenetic (methylation) and
other molecular technologies and assist physicians with the
diagnosis and prognosis of urologic cancers and other urologic
diseases. The Company’s U.S. headquarters and laboratory operations
are in Irvine, California, with additional laboratory operations in
Plano, Texas. European headquarters are in Herstal, Belgium, with
laboratory operations in Nijmegen, The Netherlands. For more
information, visit mdxhealth.com and follow us on social media at:
twitter.com/mdxhealth, facebook.com/mdxhealth and
linkedin.com/company/mdxhealth.
For more
information:mdxhealthinfo@mdxhealth.com
LifeSci Advisors (IR & PR)US: +1 949 271
9223ir@mdxhealth.com
NOTE: The mdxhealth logo,
mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate
Score, GPS and Monitor mdx are trademarks or registered trademarks
of MDxHealth SA. The GPS test was formerly known as and is
frequently referenced in guidelines, coverage policies,
reimbursement decisions, manuscripts and other literature as
Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate
Score, and Oncotype Dx Prostate Cancer Assay, among others. The
Oncotype DX trademark, and all other trademarks and service marks,
are the property of their respective owners.
MDxHealth (EU:MDXH)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
MDxHealth (EU:MDXH)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024